Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Deutsche Beteiligungs Confirms 2026 NAV per Share Guidance of €32–€36

Deutsche Beteiligungs Confirms 2026 NAV per Share Guidance of €32–€36

BitgetBitget2026/11/05 10:02
  • Deutsche Beteiligungs confirmed its adjusted fiscal 2026 guidance, targeting net asset value per share of €32–€36.
  • Fund Investment Services EBITA is expected to reach €9 million–€11 million.
  • The July 16 revision lowered NAV guidance from €36–€40 per share, raising EBITA expectations from €5 million–€9 million.
  • At September 30, NAV per share stood at €33.84; nine-month Fund Investment Services EBITA reached €10.1 million.
  • Lower peer-group valuation multiples remained the main NAV headwind, with third-quarter recovery only partly offsetting first-half declines.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Deutsche Beteiligungs AG published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss